Inhalation of dimethyl fumarate-encapsulated solid lipid nanoparticles attenuate clinical signs of experimental autoimmune encephalomyelitis and pulmonary inflammatory dysfunction in mice

• DOI: 10.1042/cs20210792
• Publication Date: 2021-12-14T12:56:32Z
• Authors: Bárbara Fernandes...; Lorena Natasha Br...; Gisela Bevilacqua...; Camila Simões Fre...; Lucas Kraemer; Fabrício Marcus S...; Marianna Carvalho...; Flávio Afonso Gon...; Gabryella Soares ...; Samantha Ribeiro ...; Isabella Luísa da...; Fábio de Lima Leite; Anselmo Gomes de ...; Maura Regina Silv...; Onésia Cristina O...; Frederico Mariane...; Ricardo Toshio Fu...; Alexander Birbrair; Remo Castro Russo; Juliana Carvalho-...
• Keywords: Solid lipid nanoparticle

The FDA-approved Dimethyl Fumarate (DMF) as an oral drug for Multiple Sclerosis (MS) treatment based on its immunomodulatory activities. However, it also caused severe adverse effects mainly related to the gastrointestinal system.